Brain Metastases - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Brain Metastases – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Brain Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Brain Metastases: Overview
Brain metastases are the most common intracranial tumor in adults and may affect up to 200,000 patients per year. The three most common primary malignancies that metastasize to the brain are lung, breast, and melanoma. Additional cancers with brain metastases include renal cell, colorectal cancer, and gynecologic cancers. Signs and symptoms caused by brain metastases can vary based on the location, size and rate of growth of the metastatic tumors. About one third of patients with another type of cancer will develop one or more metastatic brain tumors. The risk for metastatic brain tumors begins to increase after age 45 and is highest in those over 65. Signs and symptoms of brain metastases include: Headache, sometimes with vomiting or nausea, mental changes, such as increasing memory problems, Seizures, and Weakness or numbness on one side of the body. Brain metastasis diagnosis is suspected through thorough physical examination and history. Brain metastasis can be diagnosed utilizing the following tests: Computed Axial Tomography, Magnetic Resonance Imaging and others. Treatment varies with the size and type of the tumor, the primary site of the malignancy, its extent both locally and in the rest of the body (staging), the general health of the individual and presence of other significant medical problems.
'Brain Metastases - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain Metastases pipeline landscape is provided which includes the disease overview and Brain Metastases treatment guidelines. The assessment part of the report embraces, in depth Brain Metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Brain Metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Brain Metastases Emerging Drugs
Further product details are provided in the report..
Brain Metastases: Therapeutic Assessment
This segment of the report provides insights about the different Brain Metastases drugs segregated based on following parameters that define the scope of the report, such as:
Brain Metastases: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Metastases therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Metastases drugs.
Brain Metastases Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Brain Metastases – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Brain Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Brain Metastases: Overview
Brain metastases are the most common intracranial tumor in adults and may affect up to 200,000 patients per year. The three most common primary malignancies that metastasize to the brain are lung, breast, and melanoma. Additional cancers with brain metastases include renal cell, colorectal cancer, and gynecologic cancers. Signs and symptoms caused by brain metastases can vary based on the location, size and rate of growth of the metastatic tumors. About one third of patients with another type of cancer will develop one or more metastatic brain tumors. The risk for metastatic brain tumors begins to increase after age 45 and is highest in those over 65. Signs and symptoms of brain metastases include: Headache, sometimes with vomiting or nausea, mental changes, such as increasing memory problems, Seizures, and Weakness or numbness on one side of the body. Brain metastasis diagnosis is suspected through thorough physical examination and history. Brain metastasis can be diagnosed utilizing the following tests: Computed Axial Tomography, Magnetic Resonance Imaging and others. Treatment varies with the size and type of the tumor, the primary site of the malignancy, its extent both locally and in the rest of the body (staging), the general health of the individual and presence of other significant medical problems.
'Brain Metastases - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain Metastases pipeline landscape is provided which includes the disease overview and Brain Metastases treatment guidelines. The assessment part of the report embraces, in depth Brain Metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastases R&D. The therapies under development are focused on novel approaches to treat/improve Brain Metastases.
This segment of the Brain Metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Brain Metastases Emerging Drugs
- Icotinib: Betta Pharmaceuticals
- HBI-8000: HUYA Bioscience International
- ANG1005: Angiochem
- AZD3759: Alpha BioPharma
Further product details are provided in the report..
Brain Metastases: Therapeutic Assessment
This segment of the report provides insights about the different Brain Metastases drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Brain Metastases
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Brain Metastases: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Metastases therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Metastases drugs.
Brain Metastases Report Insights
- Brain Metastases Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Brain Metastases drugs?
- How many Brain Metastases drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Metastases?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Brain Metastases therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Brain Metastases and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Brain Metastases: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Brain Metastases – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Brain Metastases companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Brain Metastases Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Icotinib: Betta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
AZD3759: Alpha BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
BMX-001: BioMimetix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Brain Metastases Key Companies
Brain Metastases Key Products
Brain Metastases- Unmet Needs
Brain Metastases- Market Drivers and Barriers
Brain Metastases- Future Perspectives and Conclusion
Brain Metastases Analyst Views
Brain Metastases Key Companies
Appendix
Executive Summary
Brain Metastases: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Brain Metastases – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Brain Metastases companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Brain Metastases Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Icotinib: Betta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
AZD3759: Alpha BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
BMX-001: BioMimetix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Brain Metastases Key Companies
Brain Metastases Key Products
Brain Metastases- Unmet Needs
Brain Metastases- Market Drivers and Barriers
Brain Metastases- Future Perspectives and Conclusion
Brain Metastases Analyst Views
Brain Metastases Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Brain Metastases
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Brain Metastases
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Brain Metastases
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Brain Metastases
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
